Xoma Corp. (NASDAQ:XOMA)‘s stock had its “market perform” rating restated by analysts at Cowen and Company in a note issued to investors on Monday.

Several other equities research analysts also recently issued reports on the company. Wedbush reissued an “outperform” rating and issued a $3.00 price objective (up from $1.42) on shares of Xoma Corp. in a research note on Friday, September 16th. Zacks Investment Research downgraded Xoma Corp. from a “buy” rating to a “hold” rating in a research note on Friday, August 26th. Finally, Jefferies Group reissued a “hold” rating on shares of Xoma Corp. in a research note on Friday, August 5th. Five research analysts have rated the stock with a hold rating and one has issued a buy rating to the stock. The company has an average rating of “Hold” and an average price target of $1.81.

Analyst Recommendations for Xoma Corp. (NASDAQ:XOMA)

Xoma Corp. (NASDAQ:XOMA) opened at 0.51 on Monday. Xoma Corp. has a 52-week low of $0.44 and a 52-week high of $2.03. The firm has a market capitalization of $61.50 million, a price-to-earnings ratio of 46.36 and a beta of 2.70. The company’s 50-day moving average price is $0.61 and its 200 day moving average price is $0.68.

Xoma Corp. (NASDAQ:XOMA) last announced its quarterly earnings data on Wednesday, August 3rd. The company reported ($0.13) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by $0.01. The company earned $0.40 million during the quarter, compared to analysts’ expectations of $0.84 million. During the same period in the prior year, the company posted ($0.20) earnings per share. Equities research analysts predict that Xoma Corp. will post ($0.47) earnings per share for the current year.

Hedge funds and other institutional investors have recently modified their holdings of the company. Vanguard Group Inc. raised its position in shares of Xoma Corp. by 19.6% in the second quarter. Vanguard Group Inc. now owns 5,321,901 shares of the company’s stock valued at $2,934,000 after buying an additional 871,594 shares during the last quarter. Jacobs Levy Equity Management Inc. purchased a new position in shares of Xoma Corp. during the first quarter valued at $374,000. Paloma Partners Management Co purchased a new position in shares of Xoma Corp. during the second quarter valued at $185,000. Bellevue Group AG purchased a new position in shares of Xoma Corp. during the first quarter valued at $174,000. Finally, Spark Investment Management LLC raised its position in shares of Xoma Corp. by 100.9% in the second quarter. Spark Investment Management LLC now owns 203,900 shares of the company’s stock valued at $112,000 after buying an additional 102,400 shares during the last quarter. 17.13% of the stock is currently owned by institutional investors.

About Xoma Corp.

XOMA Corporation is a development-stage biotechnology company. The Company focuses on the discovery and development of monoclonal antibody-based therapeutics. It has five products in its endocrine portfolio, two of which are developed as part of its XOMA Metabolism (XMet) platform. Its products include XOMA 358, XOMA 129, XOMA 213 and Gevokizumab.

5 Day Chart for NASDAQ:XOMA

Receive News & Ratings for Xoma Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xoma Corp. and related companies with Analyst Ratings Network's FREE daily email newsletter.